Clinical Trials
32 trialsinMMyCAR
Kelonia Therapeutics, Inc.
GRALE
Baylor College of Medicine
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
CASPALLO
Baylor College of Medicine
DOTTI
Baylor College of Medicine
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Case Comprehensive Cancer Center
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
OriCell Therapeutics Co., Ltd.
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
Nordic Nanovector
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Celularity Incorporated
PREVALE
Baylor College of Medicine
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
University of Michigan Rogel Cancer Center
Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma
Jonsson Comprehensive Cancer Center
MALTED
Baylor College of Medicine
EUCLID
Baylor College of Medicine
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Nordic Nanovector
E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Eisai Inc.
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
New York Medical College
Clofarabine in Chronic Lymphocytic Leukemia
FDA Office of Orphan Products Development
Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma
Seagen Inc.
A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
Seagen Inc.
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
Seagen Inc.
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
Seagen Inc.
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
Children's Oncology Group
P05538
AVEO Pharmaceuticals, Inc.
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders
M.D. Anderson Cancer Center
Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer
Cancer Research UK
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
Roswell Park Cancer Institute
Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders
NIH AIDS Clinical Trials Information Service